Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 6 de 6
Filtrar
Mais filtros










Intervalo de ano de publicação
1.
AJNR Am J Neuroradiol ; 34(10): 1901-7, 2013 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-23449656

RESUMO

BACKGROUND AND PURPOSE: In the clinical setting, there is a need to perform mismatch measurements quickly and easily on the MR imaging scanner to determine the specific amount of treatable penumbra. The objective of this study was to quantify the agreement of the ABC/2 method with the established planimetric method. MATERIALS AND METHODS: Patients (n = 193) were selected from the NINDS Natural History Stroke Registry if they 1) were treated with standard intravenous rtPA, 2) had a pretreatment MR imaging with evaluable DWI and PWI, and 3) had an acute ischemic stroke lesion. A rater placed the linear diameters to measure the largest DWI and MTT lesion areas in 3 perpendicular axes-A, B, and C-and then used the ABC/2 formula to calculate lesion volumes. A separate rater measured the planimetric volumes. Multiple mismatch thresholds were used, including MTT volume - DWI volume ≥50 mL versus ≥60 mL and (MTT volume - DWI volume)/MTT volume ≥20% versus MTT/DWI = 1.8. RESULTS: Compared with the planimetric method, the ABC/2 method had high sensitivity (0.91), specificity (0.90), accuracy (0.91), PPV (0.90), and NPV (0.91) to quantify mismatch by use of the ≥50 mL definition. The Spearman correlation coefficients were 0.846 and 0.876, respectively, for the DWI and MTT measurements. The inter-rater Bland-Altman plots demonstrated 95%, 95%, and 97% agreement for the DWI, MTT, and mismatch measurements. CONCLUSIONS: The ABC/2 method is highly reliable and accurate for quantifying the specific amount of MR imaging-determined mismatch and therefore is a potential tool to quickly calculate a treatable mismatch pattern.


Assuntos
Imageamento por Ressonância Magnética/métodos , Imageamento por Ressonância Magnética/normas , Acidente Vascular Cerebral/patologia , Idoso , Idoso de 80 Anos ou mais , Feminino , Fibrinolíticos/uso terapêutico , Humanos , Imageamento por Ressonância Magnética/estatística & dados numéricos , Masculino , Pessoa de Meia-Idade , Variações Dependentes do Observador , Valor Preditivo dos Testes , Recuperação de Função Fisiológica , Sistema de Registros , Reprodutibilidade dos Testes , Sensibilidade e Especificidade , Acidente Vascular Cerebral/tratamento farmacológico , Ativador de Plasminogênio Tecidual/uso terapêutico
2.
Food Microbiol ; 24(1): 75-81, 2007 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-16943097

RESUMO

Bacteriophage infections of starter lactic acid bacteria are a serious risk in the dairy industry. Phage infection can lead to slow lactic acid production or even the total failure of fermentation. The associated economic losses can be substantial. Rapid and sensitive methods are therefore required to detect and identify phages at all stages of the manufacture of fermented dairy products. This study describes a simple and rapid multiplex PCR method that, in a single reaction, detects the presence of bacteriophages infecting Streptococcus thermophilus and Lactobacillus delbrueckii, plus three genetically distinct 'species' of Lactococcus lactis phages commonly found in dairy plants (P335, 936 and c2). Available bacteriophage genome sequences were examined and the conserved regions used to design five pairs of primers, one for each of the above bacteriophage species. These primers were designed to generate specific fragments of different size depending on the species. Since this method can detect the above phages in untreated milk and can be easily incorporated into dairy industry routines, it might be readily used to earmark contaminated milk for use in processes that do not involve susceptible starter organisms or for use in those that involve phage-deactivating conditions.


Assuntos
Bacteriófagos/isolamento & purificação , Contaminação de Alimentos/análise , Leite/virologia , Reação em Cadeia da Polimerase/métodos , Animais , Bacteriófagos/classificação , Sequência de Bases , Bovinos , Qualidade de Produtos para o Consumidor , Fermentação , Humanos , Lactobacillus delbrueckii/virologia , Lactococcus lactis/virologia , Leite/microbiologia , Dados de Sequência Molecular , Sensibilidade e Especificidade , Streptococcus thermophilus/virologia
3.
Medicina (B.Aires) ; 53(3): 207-210, mai.-jun. 1993.
Artigo em Espanhol | LILACS | ID: lil-320002

RESUMO

A pharmacokinetic study of ceftazidime was performed in newborn children. Six premature infants with a body weight up to 2000 g and with symptoms of pneumonia (Table 1) were treated with ceftazidime (50 mg/kg body weight) by endovenous route. Plasma concentrations of the antibiotic (Fig. 1) were determined by HPLC. A kinetic behavior was described through a compartment model independent analysis. The calculated parameters were as follows: half-life (T1/2z = 4.05 +/- 0.81 h) apparent volume of distribution (Vz = 686.0 +/- 258.6 ml/kg), elimination rate constant (lambda z = 0.18 +/- 0.04h-1), area under curve (AUC = 464.4 +/- 139.1 mu gh/ml, mean residence time (MRT = 5.2 +/- 1.3 h), and total clearance (CI = 114.9 +/- 30.0 ml/h. kg) (Table 2). Good correlation was observed (r = 0.83, p < 0.05 between lambda z = and Vz). The loading and maintenance doses calculated for enterobacteria and P. aeruginosa were 15 and 13 mg/kg i.v. respectively each 12 h.


Assuntos
Humanos , Masculino , Feminino , Recém-Nascido , Lactente , Ceftazidima , Doenças do Prematuro/metabolismo , Pneumonia , Recém-Nascido de Baixo Peso/metabolismo , Ceftazidima , Doenças do Prematuro/tratamento farmacológico , Enterobacteriaceae , Pneumonia
4.
Medicina [B.Aires] ; 53(3): 207-210, may.-jun.1993.
Artigo em Espanhol | BINACIS | ID: bin-7452

RESUMO

A pharmacokinetic study of ceftazidime was performed in newborn children. Six premature infants with a body weight up to 2000 g and with symptoms of pneumonia (Table 1) were treated with ceftazidime (50 mg/kg body weight) by endovenous route. Plasma concentrations of the antibiotic (Fig. 1) were determined by HPLC. A kinetic behavior was described through a compartment model independent analysis. The calculated parameters were as follows: half-life (T1/2z = 4.05 +/- 0.81 h) apparent volume of distribution (Vz = 686.0 +/- 258.6 ml/kg), elimination rate constant (lambda z = 0.18 +/- 0.04h-1), area under curve (AUC = 464.4 +/- 139.1 mu gh/ml, mean residence time (MRT = 5.2 +/- 1.3 h), and total clearance (CI = 114.9 +/- 30.0 ml/h. kg) (Table 2). Good correlation was observed (r = 0.83, p < 0.05 between lambda z = and Vz). The loading and maintenance doses calculated for enterobacteria and P. aeruginosa were 15 and 13 mg/kg i.v. respectively each 12 h.(Au)


Assuntos
Humanos , Masculino , Feminino , Recém-Nascido , Lactente , Ceftazidima/farmacocinética , Recém-Nascido de Baixo Peso/metabolismo , Doenças do Prematuro/metabolismo , Pneumonia/metabolismo , Ceftazidima/uso terapêutico , Enterobacteriaceae/metabolismo , Doenças do Prematuro/tratamento farmacológico , Pneumonia/tratamento farmacológico
5.
Medicina (B Aires) ; 53(3): 207-10, 1993.
Artigo em Espanhol | MEDLINE | ID: mdl-8114628

RESUMO

A pharmacokinetic study of ceftazidime was performed in newborn children. Six premature infants with a body weight up to 2000 g and with symptoms of pneumonia (Table 1) were treated with ceftazidime (50 mg/kg body weight) by endovenous route. Plasma concentrations of the antibiotic (Fig. 1) were determined by HPLC. A kinetic behavior was described through a compartment model independent analysis. The calculated parameters were as follows: half-life (T1/2z = 4.05 +/- 0.81 h) apparent volume of distribution (Vz = 686.0 +/- 258.6 ml/kg), elimination rate constant (lambda z = 0.18 +/- 0.04h-1), area under curve (AUC = 464.4 +/- 139.1 mu gh/ml, mean residence time (MRT = 5.2 +/- 1.3 h), and total clearance (CI = 114.9 +/- 30.0 ml/h. kg) (Table 2). Good correlation was observed (r = 0.83, p < 0.05 between lambda z = and Vz). The loading and maintenance doses calculated for enterobacteria and P. aeruginosa were 15 and 13 mg/kg i.v. respectively each 12 h.


Assuntos
Ceftazidima/farmacocinética , Recém-Nascido de Baixo Peso/metabolismo , Doenças do Prematuro/metabolismo , Pneumonia/metabolismo , Ceftazidima/uso terapêutico , Enterobacteriaceae/metabolismo , Feminino , Humanos , Lactente , Recém-Nascido , Doenças do Prematuro/tratamento farmacológico , Masculino , Pneumonia/tratamento farmacológico
6.
Medicina [B Aires] ; 53(3): 207-10, 1993.
Artigo em Espanhol | BINACIS | ID: bin-37734

RESUMO

A pharmacokinetic study of ceftazidime was performed in newborn children. Six premature infants with a body weight up to 2000 g and with symptoms of pneumonia (Table 1) were treated with ceftazidime (50 mg/kg body weight) by endovenous route. Plasma concentrations of the antibiotic (Fig. 1) were determined by HPLC. A kinetic behavior was described through a compartment model independent analysis. The calculated parameters were as follows: half-life (T1/2z = 4.05 +/- 0.81 h) apparent volume of distribution (Vz = 686.0 +/- 258.6 ml/kg), elimination rate constant (lambda z = 0.18 +/- 0.04h-1), area under curve (AUC = 464.4 +/- 139.1 mu gh/ml, mean residence time (MRT = 5.2 +/- 1.3 h), and total clearance (CI = 114.9 +/- 30.0 ml/h. kg) (Table 2). Good correlation was observed (r = 0.83, p < 0.05 between lambda z = and Vz). The loading and maintenance doses calculated for enterobacteria and P. aeruginosa were 15 and 13 mg/kg i.v. respectively each 12 h.

SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...